In a recent note, Zacks Small-Cap Research (Zacks SCR) has valued Canadian drug developer Nurexone Biologic, which trades in the U.S., at $2.55 per share, more than five times the current share price. In the over-the-counter market on Tuesday, December 3, the stock was quoted at $0.50 per share. Details …